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Aim. To evaluate in vitro the antibacterial effect of a paper made of silver phosphate cellulose fibers (SPCF) on Staphylococcus
aureus, the most common diabetic foot ulceration (DFU) pathogen when compared with other common commercial products.
Methods. *e antibacterial activity of SPCF samples was evaluated through time with cell counting on agar plates. SPCF samples
were then compared with commercial wound care products currently in use in DFU treatments (Silvercel™, Acticoat 7, and
Aquacel Ag ExtraTM) through time on agar plates (growth inhibition zones). Results. After 6 hours, there was no viable bacterial
cell detected on either plate (p< 0.05). *ere was a net growth inhibition zone for SPCF samples but no significant difference
between the two silver concentrations. Compared with common commercial products, SPCF paper provides results equal to
Acticoat 7 (p< 0.05) and superior to Aquacel AG ExtraTM and Silvercel™ at lower silver concentrations (p< 0.001). Conclusions.
*ese results have shown the efficiency of SPCF paper to eliminate Staphylococcus aureus in these conditions. SPCF papers are
effective when compared with other common commercial products and could have an industrial potential in wound care. Infected
DFU could benefit from the antibacterial effectiveness of SPCF, but more relevant experimentations related to foot ulcers
are needed.
1. Introduction
Diabetes foot infection (DFI) is a widespread, complex, and
costly problem to treat. It is one of the major complications
of diabetic foot ulcers (DFU), which can lead to lower ex-
tremity amputation and mortality [1–3]. *e 5-year mor-
tality rate following a DFU episode is between 43% and 55%
and up to 74% with a lower-extremity amputation [4]. DFI is
considered to be the predominant cause of hospitalization in
patients with diabetes, accounting for about 20% of total
diabetes-related hospital admissions in North America [2].
*e new wound infection continuum and DFI studies have
shown that DFU must be automatically considered infected
and that healthcare providers should apply the latest rec-
ommendations for biofilm-based wound care and holistic
infection management [5–8]. DFI is caused by multiple
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bacterial strains, but the main pathogen involved in DFU is
Staphylococcus aureus [9, 10]. However, with the different
stages of the continuum and healing delays caused by dense
colonization, bacterial tolerance to several forms of treat-
ments, and its subsequent immune response, several gaps
remain in understanding the management of this infection,
particularly in DFI caused by biofilms. *ere is a distinct
clinical need to understand DFI caused by biofilm, and the
scientific community needs more evidence concerning its
role and impacts in order to manage it optimally [5, 11, 12].
*erefore, this study evaluate the effectiveness of another
material, made with old molecule, against biofilm-forming
bacterial strains and safe for the patient [12–15]. Several
elements can interfere with research on wound care prod-
ucts, such as unknown antibacterial molecules effectiveness,
standardized methods, and regulatory guidelines to establish
the performance of targeted molecules. *ese few examples
limit the implication of the industry and end up driving up
the cost of research and development, despite the need for
clinical trials [16]. In that context, the objective of this study
was to conduct a preliminary examination of a potential
antibacterial material that uses pulp and paper expertise for
biomedical purposes. Cellulose is a well-known, low-cost
raw material widely used in wound care, while silver is also
recognized for its antibacterial effectiveness [17–20]. *e
wound care community remains skeptical and conservative
about the widespread use of antibacterial dressings and
silver, even with the new evidence proposed in the wound
infection continuum [5, 10]. *is can be explained by
bacterial resistance due to overuse or inappropriate use and
cytotoxicity of antibacterial molecules, which are barriers to
healing and harmful for the patient [21]. *ese products are
also expensive [5, 21–23]. Few occurrences of resistance to
silver have been reported in the medical literature, and the
cellular sensitivity is correlated with the level of silver release
and exposure [14, 15, 24, 25]. *e material we tested, a paper
composed of silver phosphate cellulose fibers (SPCF), is
composed of silver ions, which is the form of silver already
effective against bacteria and fungi through enzymatic
systems, blocking respiratory cycle and destroying cell wall
membrane [26, 27].
In the context where DFUs should always be consid-
ered infected, a recent Cochrane intervention review
suggests that DFU healing will be superior with antibac-
terial wound dressing than without it [17]. *ese results
correspond with 119 additional healing events with an
antibacterial dressing in 1000 participants (95% CI from 51
to 191 more) [17]. *ereby, the aim of this study is to
evaluate the antibacterial effect of silver phosphate cellu-
lose fiber (SPCF) paper on planktonic Staphylococcus
aureus potentially film-forming, by standard susceptibility
testing in vitro. *e objectives are to (1) determine the
antibacterial effect of two concentrations of SPCF by time,
from a stock solution of Staphylococcus aureus and (2)
compare SPCF samples to commercial products generally
used in wound care for DFU (Silvercel™, Acticoat 7, and
Aquacel Ag Extra™), which also use silver as an antibac-
terial agent, on an agar plate by growth inhibition zone
(clear zone).
2. Materials and Methods
2.1. Media and Bacterial Strain. *emedia used in this study
were tryptic-soy agar (TSA) and tryptic-soy broth (TSB)
(Difco Laboratories, Detroit, MI, USA). Media were auto-
claved for 30min at 120°C. Staphylococcus aureus (ATCC®25923™), provided by the microbiology laboratory of the
Université du Québec à Trois-Rivières was the strain spe-
cifically selected for its biofilm forming potential, consid-
ering its adhesion properties [28]. *e strain was grown on
TSA at 37°C.
2.2. Preparation of SPCF Samples. Bleached softwood Kraft
fibers (provided by Kruger Trois-Rivières Mill, Trois-Riv-
ières, Canada) were phosphorylated using an original
method developed by one of the authors, Dan Belosinschi
[29]. *e phosphate moiety grafted at the fibers’ surface
electronegativity charges in water and behaves as an ad-
sorption site for cations like silver ions. *erefore, an iso-
therm of adsorption was conducted at room temperature for
15 minutes by contacting the phosphorylated fibers with
silver nitrate, AgNO3 0.1N (Sigma-Aldrich, St. Louis, USA),
in deionized water. An excess of 20% (weight/weight) of
silver was dosed to reach the target values of 0.075 and
0.15mg/cm2 (mg of silver to cm2 of paper). For this pre-
liminary testing, we chose the amount of silver for SPCF’s
samples based on the commercial dressings, chosen as
comparisons for the second objective of this experiment
(Table 1). According to a previous publication, theoretical
exact amount of ionic silver can be calculated from total
phosphorus charges (our SPCF sample was 5000mmoles/
kg); practical adjustment was done to obtain targeted
concentrations [33]. *e exact amount of ionic silver was
determined by analysis with spectrometry (plasma micro-
waves atomic emission spectrometer, MP-AES) [33]. At the
end of adsorption isotherm, the fibers were thoroughly
washed with deionized water to remove the nitrate and the
free silver ions (Figure 1). Finally, hand sheet papers with a
basis weight of 60 g/m2 were made from silver phosphate
cellulose fibers (SPCF) using the standard method of the
pulp and paper industry—Tappi T 205 sp-02. SPCF keeps
their morphology from unmodified cellulose fibers, but
mechanical and surface properties are different (Figure 2).
For example, SPCF strength properties are very low, but that
can be compensated by mixing SPCF and unmodified cel-
lulose fibers to keep its original properties with antibacterial
properties [29, 34, 35]. SPCF samples had a brown color (see
samples represented in Figure 3). It is well known that
substrate treated with AgNO3 exhibits brown color in
aqueous solution due to excitation of surface plasmon vi-
brations of silver particles [36]. Samples of 2× 2 cm from the
commercial dressing and from SPCF samples were prepared
under sterile conditions in triplicate.
2.3. Experimental Protocol. To reach the first objective of this
study, a stock solution was prepared with a full loop of
Staphylococcus aureus transferred to a shake flask of 250ml
with sterile TSB. *e incubation was carried out overnight
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(approximately 18 h) under conditions of 125 rpm agitation
and 37°C. Bacterial cell concentration was measured by
colony-forming units (CFU)/ml using the plate count agar
technique combined with optical density on a spectropho-
tometer at 600 nm length wave (Cary 5000UV/Vis Spec-
trometer, Agilent Technologies, USA). *e working culture
solution was prepared by diluting the stock in a sterile saline
solution (0.85% sodium chloride). An aliquot of 10ml of
working culture solution was distributed to 50ml Falcon
tubes, and SPCF samples were placed on the top of the
solution in the tube. *us, the samples were totally sub-
merged by capillarity and in contact with the liquid surface
of the working culture solution without causing the disso-
lution of cellulosic fibers in the aqueous environment. Sterile
gauze (unmodified cellulose fibers) was used as a negative
control, and the experiment was performed in triplicate.
Sampling was carried out at 0, 3, 6, 9, 12, 24, 36, and 48 h and
kept at 4°C for analysis. *e final bacterial cell concentration
Table 1: Characteristics of dressing from the industry with silver and its antimicrobial effect.
Dressing Material Silver composition Antimicrobial effect
Aquacel Ag extra (ConvaTec, Deeside,
UK) [30]
2 nonwoven layers of sodium CMC
fibers
Approximately 1.2% w/w or
0.17mg/cm2
After 30min up to
14 days
Acticoat 7 (Smith & Nephew, London,
UK) [31]
3 layers of a metallic (nano) crystalline
silver-encrusted HDPE mesh
alternating with two layers of a rayon
polyester nonwoven fabric, bonded at
intervals by ultrasonic welding of the
HDPE
Approximately 8.4% w/w or 1.48mg/
cm2 After 30min up to 7 days
Silvercel (Acelity, San Antonio, USA)
[32]
Nonwoven fabric comprised of a blend
of metallic silver-coated nylon fibers
and calcium alginate/CMC fibers
between two apertured sheets of EMA
Approximately 4% w/w or
1.11mg/cm2 silver Up to 7 days
Gauze (Alliance, MedicalMart,
Mississauga Canada) 2 layers of nonwoven cotton (cellulose) None None (control)





































































































Figure 1: SPCF formation: interactions of silver ions with cellulose fibers.
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in the sample was measured by the plate count agar tech-
nique in triplicate.
For the second objective, the working culture was pre-
pared as described in the first objective, and 106 CFU/ml
bacterial cells were inoculated on the surface of TSA in order
to obtain a bacterial lawn of Staphylococcus aureus. Wound
infection is described in the literature as a bacterial load of
≥105 CFUs, and it has been hypothesized that this bacterial
load may correspond to infected wounds with biofilm
[5, 37]. *en, we hypothesized that the bacterial value for
antibacterial testing should be 106 CFUs. SPCF samples
should be effective at this bacterial concentration and at least
demonstrate an inhibition growth zone. *ereafter, SPCF
samples, Silvercel™, Acticoat7, Aquacel Ag Extra™, and
gauze (as the negative control) were sterilely placed on the
center of the TSA plates and incubated at 37°C. *e ob-
servations were carried out at 6, 24, 48, and 72 h, and the
experiment was performed in triplicate. Growth inhibition
zones in the TSA were measured with a digital caliper (Insize
Series 1102, Global industrial, USA).
2.4. Statistical Methods. For the first objective, statistical
variation of results was expressed by means of bacterial cell
counts (in log10), with standard deviations of 5% between
triplicates, for each sample. For the second objective, the
measurement accuracy of the digital caliper was ±0.02mm
with a resolution of 0.01mm. *e variation between sample
sizes was measured with a coefficient of correlation
(R� 0.915), meaning that sample size did not influence the
measures. A two-dimensional analysis of variance with re-
peated measurement (Anova A×Br) and a t test mean
comparison according to the Dunn–Sidàk correction (which
allow multiple comparisons) was performed for some
samples to determine any statistically significant differences
between the most efficient samples at p< 0.05 (Excel,
Microsoft Office 2013, USA).
3. Results and Discussion
3.1. Antibacterial Effect of SPCF. Figure 4 illustrates the
antibacterial effect of two concentrations of SPCF by time,
from a stock solution of Staphylococcus aureus, in these in
(a) (b)
Figure 2: (a) Unmodified cellulose fibers and (b) SPCF (scanning electron microscopy (SEM), JSM T300, JEOL).











Figure 3: Growth inhibition representations for control, SPCF
samples, and commercial products on Staphylococcus aureus at 6,



















Figure 4: Plot of Staphylococcus aureus (CFU/ml for control) and
SPCF samples by time.
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vitro conditions. *e total viable counts of Staphylococcus
aureus reveal no survivor cell after 6 hours for both samples.
*ere is a reduction of 1 log10 after 1 h, 5 log10 after 3 h, and 7
log10 after 6 h for both samples. Low standard deviation
(between triplicates for each period) indicates a good re-
producibility, and that there is no significant difference on the
bacterial cell count between samples. *ere is a significant
difference with the control at 3, 9, 12, 24, and 48 h (p< 0.05).
3.2. Comparisons of SPCF Samples with Commercial Products.
Figure 4 represents growth inhibition for each sample, by
time (6, 24, 48, and 72 h). It was found that all samples
prevented Staphylococcus aureus growth except for the
control sample. Figure 5 represents the growth inhibition
zone for each sample by time, taking into consideration the
variations of paper size with standard deviation and the
trend with the overall sample means. First, at 6 h, SPCF
samples were superior to the overall mean and to com-
mercial products, and Aquacel AG Extra™ was the most
efficient commercial sample. *en at 24 h, SPCF samples
remained superior and Aquacel AG Extra™ became less
effective than Acticoat 7. At 48 h, SPCF samples were still
superior and Acticoat 7 was still the most efficient com-
mercial product. Finally, at 72h, SPCF 0.15mg/cm2 was
superior and Acticoat 7 remained the most efficient com-
mercial product. Silvercel™ was the least efficient sample for
the timing period. In addition, all SPCF samples were su-
perior to the overall mean. Results were significant between
samples (p< 0.001), for different time measurements
(p< 0.001) and for both (p< 0.01).*e antibacterial effect of
SPCF samples duration was of a minimum of 72 h according
to this second part of the experiment.
Following this trend, samples comparisons were per-
formed between the SPCF samples and the Aquacel AG
Extra™ and Acticoat 7. *e results presented superior effects
of SPCF 0.075mg/cm2 (p< 0.001) and 0.15mg/cm2
(p< 0.01) when compared with Aquacel AG Extra™, and
SPCF 0.15mg/cm2 (p< 0.05), when compared with Acticoat
7. *ere is no significant difference between the SPCF
0.0.075mg/cm2 sample and Acticoat 7. Furthermore, there is
no significant difference between SPCF sample concentra-
tions’ means of efficiency over time.
4. Discussion
DFU is invariably associated with poor healing and sus-
ceptibility to recurrent infections, as it is related to the
wound infection continuum and biofilm-induced chronic
conditions. *ere is a clinical need to properly manage DFI
in order to minimize the impact of bacterial colonization
and promote healing. *e goals of treating a DFI are the
eradication of the infection and the avoidance of soft-tissue
loss and amputation. It has been shown that the use of
standard antibiotics and antiseptics is not necessarily the
optimal treatment option because biofilm is remarkably
resistant to these antibacterial agents [3, 11]. *e biofilm-
based wound care may be a solution [5, 12]. However, this
approach requires the use of antibacterial dressing at each
debridement, an important step of this approach, which
could lead to other problems like bacterial resistance to
silver, cellular cytotoxicity, and allergic reactions (hyper-
sensitivity exposure) [14, 20, 38, 39]. Human cytotoxicity to
silver is increased with silver concentration and bio-
accumulation, causing severe local inflammation and a large
intracellular and intercellular edema to fibroblasts and
keratinocytes [21, 38]. Silver-containing dressings release
silver into the wound, maintaining the elevated concen-
tration (up to 70 ppm) for its antibacterial effectiveness
during several days, which is also above the toxic threshold
for these important healing cells [21, 40, 41]. *ese phe-
nomena have been documented with silver exposition and
overuse [14, 25, 42, 43]. *erefore, the use of silver needs to
be carefully considered. However, the effectiveness of silver
is well documented as an effective antibacterial agent against
biofilm; it is also able to inhibit 115 clinical bacterial strains
isolated from wounds [44–46]. It is the most widely metal
used in wound dressing research with cellulose and com-
posite [47]. It induces less bacterial resistance in comparison
to antibiotics because of its mechanism of action (multiple
sites) [15, 39, 48, 49]. Silver tolerance has been documented
in biofilm strains compared with planktonic strains. Studies
have documented that higher levels of silver (up to 4 times
thanminimal inhibitory concentration (MIC)) are needed to
treat bacteria that colonize biofilm [50, 51]. *us, it is im-
perative to identify alternative products against biofilm with
less deleterious effects and more effective ways to deliver
ionic components [48].
*e evaluation of a new antibacterial paper, silver
phosphorylated cellulose fibers, as an innovative way to
deliver silver ions rapidly and efficiently in in vitro condi-
tions on planktonic Staphylococcus aureus was our goal.
Compared with commercial products which sustained re-
lease of silver ions at the wound surface from ionic reactions
to solubilized AgNO3 by wound exudate or moisture of the
skin (fluid) and oxygen, SPCF, by its innovative way to
incorporating ionic silver, released bactericidal components
immediately at the contact area [27, 35]. *is presentation



























Figure 5: Means of growth inhibition of Staphylococcus aureus and
overall mean, by time for SPCF samples and commercial products
(control is not presented in the graph because it is equal to 0mm of
inhibition).
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minimizing survival rates and the emergence of mutation
and resistance [40]. *is is interesting in the context of
wound cares, particularly with limitations of dry wounds
(less exudative) or diabetic wounds which had tissue hypoxia
and limited moisture [52]. *e antibacterial effect of silver is
related to the amount of silver and the rate of its release, the
distribution of silver, and the chemical and physical forms.
*e affinity of dressing to moisture also influences the
bactericidal effect [27, 53]. In the SPCF, the specific amount
of silver ions can be calculated precisely (number of
phosphorylated groups), which is interesting for maximizing
antibacterial activity at lower silver concentration [29, 35].
Similar results between both concentrations (0.075mg/
cm2 and 0.15mg/cm2) on Staphylococcus aureus are sug-
gesting sufficient concentration of ionic silver during 72h
but it can be adjusted at a lower level.*e preliminary results
of this study show SPCF sample efficiency on Staphylococcus
aureus lawn within 6 hours, in these in vitro conditions. It
demonstrates superior or equal antibacterial effect when
compared with commercial products, which can contain as
much as the double of silver concentration than the
0.075mg/cm2 SPCF samples. *e most effective compared
product was Acticoat 7, which contains 1.48mg/cm2, about
10 times more than our highest concentration sample of
0.15mg/cm2.
*e large, immediate concentration of silver ions re-
leased will become chemically consumed and rapidly
inactivated through the formation of chemical complexes
with chloride upon contact with organic biological fluids
from the wounds [54]. However, in the wound infection
continuum, the synergetic effect of several steps over time
allows for optimal biofilm management. *e mechanical
debridement is the first step to manage bioburden (in the
wound as well as the biofilm), and the use of antibacterial
wound dressing, the final step, is used to prevent biofilm
reformation with the remaining film-forming bacteria
[5, 45]. In the biofilm life cycle, this represents a few minutes
to 4 hours (irreversible biofilm attachment and bacterial
adhesion) [55, 56]. *e active silver ion must be available as
soon as possible to prevent biofilm formation and be bac-
tericidal, as is our new paper, SPCF. Currently, the silver
inactivation is compensated for by frequent wound dressing
replacements, but this is a costly and time-consuming
problem for healthcare professionals and patients, and there
is an excess of silver in contact with the wound. *ere is also
a vicious circle to consider: silver ions are responsible for
antibacterial activity but the complex of chloride ions
produced and then deactivates the silver ions [54]. Nano-
crystalline silver, such as in Acticoat 7, has been developed in
wound care to allow a slow, stable release of silver ions to
fight this phenomenon [57, 58]. However, in this experi-
mental condition, our preliminary results demonstrate that
SPCF is more effective than Acticoat 7 (at 6 h), while having
a similar overall effect. In this context, our results are
promising in regard to the development of a new antibac-
terial paper intended for human healthcare when rapid
antibacterial efficacy is urgently needed, at low cost.
Phosphorylated cellulose fibers can incorporate other
metal ions such as zinc (Zn2+), which has interesting
antibacterial properties against Staphylococcus aureus and
Escherichia Coli, also commonly involved in DFI [59]. Zinc
has interesting properties, such as promoting cell migration
and proliferation and stimulating epithelialization in
wounds [60, 61]. *ese preliminary results demonstrate the
potential of this fiber and may be a new opportunity for the
biomedical industry. Phosphorylated cellulose maintains
natural touch of unmodified cellulose fibers and can be at all
dimensional spectrums of cellulose (macroscopic to nano-
fibers) [62]. It is a natural polymer, well known for its
biocompatibility and biodegradable properties, and can
mimic the extracellular matrix. Cellulosic derivatives en-
hance healing by stimulating several growth factors for fi-
broblasts and keratinocytes [63, 64]. Cellulose fibers are a
cheap and widely available material of choice for sustainable
development.
Nevertheless, this study presents several limitations.
First, the in vitro conditions of the study and planktonic
bacteria testing do not accurately represent the clinical
context of a wound. It has been shown that basing a therapy
on the conventional susceptibility test (MIC of a bacterium)
against biofilm-forming bacteria fails to eradicate the in-
fection. *ere is still a need for evidence to understand the
lack of correlation between MIC results and the therapeutic
success of chronic biofilm infections [5, 65]. However,
antibacterial testing of our SPCF on biofilm models is
needed [65, 66]. *ough in some human biofilm cases,
studied antimicrobial susceptibility testing on biofilm
(minimal biofilm eradication concentration (MBEC)) assays
were not superior to MIC to guide antibiotic therapy [67]. In
one small study, MBEC of Staphylococcus aureus isolated
from DFU demonstrated resistance to antibiotics at con-
centrations 10 to 1000 times higher than those required at
MIC, meaning that the antibiotic susceptibility profile
cannot be applied to biofilm-established infections, partic-
ularly in the case of DFU. In this condition, broad-spectrum
antibacterial agents are needed [12, 68, 69]. Finally, few
variables were tested in the innovation of the new fibers,
which means that further studies are needed to understand
the silver ion release, cytotoxicity, and cell interactions in a
wound model in vitro and animal model in vivo, as well as
time to efficiency and duration, mechanical and physical
properties of the SPCF (as a layer), and in combination with
other ions such as zinc. *is will allow for a better under-
standing of its potential for DFI treatment. In this per-
spective, this experiment was conducted to explore new
materials with a focus on the DFU biofilm problem, but its
potential may be much more extensive. Evidences about this
new material are scarce and preliminary, but a strength of
this study was the integrated analysis on a health issue
combining fundamental and clinical sciences. More relevant
experiments related to foot ulcers and this material are
needed.
5. Conclusions
*is is the first in vitro study of silver phosphate cellulose
fibers used on Staphylococcus aureus; it has demonstrated
antibacterial efficiency and effects comparable to
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commercial wound care products. *erefore, it is the first
step exploring a new material for wound cares or in other
areas. Further studies are needed to focus on formulation
(concentration, combination of molecules for synergic ef-
fects, etc.) and on mechanical and physical properties of the
new material.
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Vlahović, “A modified microtiter-plate test for quantification
of staphylococcal biofilm formation,” Journal of Microbio-
logical Methods, vol. 40, no. 2, pp. 175–179, 2000.
[29] D. Belosinschi, F. Brouillette, Y. Shi, J. Paradis, and J. Doucet,
“Phosphorylated lignocellulosic fibers, uses and processes of
preparation thereof,” International Patent Application,
WO2017214719A1, 2017.
[30] Y. Barnea, J. Weiss, and E. Gur, “A review of the applications
of the hydrofiber dressing with silver (Aquacel Ag®) in wound
care,” 9erapeutics and Clinical Risk Management, vol. 6,
p. 21, 2010.
[31] J. Fong and F. Wood, “Nanocrystalline silver dressings in
wound management: a review,” International Journal of
Nanomedicine, vol. 1, no. 4, pp. 441–449, 2006.
[32] M. Clark, “Alginates in dressings and wound management,”
in Alginates and 9eir Biomedical Applications, Springer,
Berlin, Germany, 2018.
[33] L. B. Ebskov, “Epidemiology of lower limb amputations in
diabetics in Denmark (1980 to 1989),” International Ortho-
paedics, vol. 15, no. 4, pp. 285–288, 1991.
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